Vidas Kube

The U.S. Food and Drug Administration (FDA), through its Office of Acquisition and Grant Services, is issuing a Request for Information (RFI) to identify potential sources capable of supplying VIDAS KUBE systems to replace discontinued VIDAS equipment currently deployed across the Office of Regulatory Testing and Surveillance (ORTS) laboratory network. This RFI is issued solely for market research and planning purposes and does not constitute a formal solicitation or commitment by the government to award a contract. Key technical requirements include modular, stackable benchtop systems supporting up to six simultaneous modules with Enzyme-Linked Fluorescent Immunoassay (ELFA) technology, processing capacity of 12-72 samples per cycle, compatibility with a minimum of 80 immunoassay tests, and compliance with 21 CFR Part 11 regulations. Notably, responses to this RFI will not be evaluated or scored, and companies responding are not guaranteed consideration in any future solicitation. The deadline for submitting responses is March 10, 2026 at 10:00 AM EST to Nina Montgomery at nina.montgomery@fda.hhs.gov, with the RFI number required in the subject line.

The procurement carries no set-aside designation and does not identify any current contractors or incumbents. The base year requirement encompasses 14 VIDAS KUBE systems—two units per location—to be delivered within 60 days to seven ORTS laboratory locations: Arkansas, Atlanta, Denver, Irvine, New York, San Francisco, and Seattle. Each system must include six modules and one PC with a minimum one-year warranty from installation, along with newly manufactured equipment delivered FOB destination with inside installation, setup, and training for up to three users per laboratory by qualified field engineers and application specialists. The RFI does not specify an award value or budget range, indicating this is preliminary market research to assess vendor capability and availability before developing a formal solicitation strategy.